Clozapine

TORONTO, Nov. 7, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and nine months ended September 30, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Q3 2024 revenue was $14.1 million, Adjusted EBITDA1 was $4.1 million and cash from operations was $1.5 million, compared to $16.0 million, $5.1 million and $5.4 million, respectively, in Q3 2023. Canadian product sales of Vascepa and Clozaril grew 11% in Canadian dollars compared to Q3 2023. Operating expenses decreased 15%, excluding cost of product sales, compared to Q3 2023. Excluding the royalty portfolio, Q3 2024 Adjusted EBITDA increased 55% to $3.9 million, compared to $2.5 million in Q3 2023. Paid down $15 million of the term loan, ending the quarter with net debt of $52.4 million compared to net debt of approximately $66.5 million at the end of Q4 2023. Named John Hanna permanent CFO and promoted Brian Walsh to Chief Commercial Officer. "Q3 saw the continued growth of our promoted products in Canada driven by the strongest quarterly growth of the year for Vascepa. In constant currency, our Q3 net sales in Canada grew 11% with Vascepa leading the way with 30% year-over-year growth," said Craig Millian, CEO at HLS. "At the same time, we significantly reduced our operating expenses in the quarter, and we made a substantial debt repayment to strengthen our balance sheet and increase our future cash flows and financial flexibility. These achievements put us in a much stronger financial and operating position entering 2025 than when we started this year." Q3 2024 BRAND PERFORMANCE HIGHLIGHTS Completed the transition of Vascepa primary care sales responsibilities from Pfizer back to HLS on August 31, 2024. Vascepa revenue in Canada increased 30% in constant currency compared to Q3 2023 while the Q3 2024 loss attributed to Vascepa was $0.6 million, the lowest since product launch and a significant sequential decrease from a loss of $1.6 million in Q2 2024. Vascepa unit demand increased by 45% compared to Q3 2023. The number of consistent prescribers2 for Vascepa increased 66% compared to Q3 2023. Clozaril revenue in Canada increased by 1% in constant currency compared to Q3 2023. Clozaril patient growth in Canada was 2% compared to Q3 2023. 2024 and 2025 OUTLOOK With the release of its Q3 2024 results, the Company is updating its 2024 revenue and Adjusted EBITDA guidance. HLS is now guiding to a lower revenue range of $56.5-57.2 million compared to the previous range of $58.5-59.7 million. The revised guidance is attributable to year-to-date U.S. Clozaril sales being behind plan and from the negative foreign exchange impact on the Company's Canadian business due to the persistent strength of the U.S. dollar relative to the Canadian dollar in 2024. The underlying demand fundamentals for U.S. Clozaril remain sound. The decline in 2024 U.S. Clozaril net sales is largely due to higher-than-typical wholesaler inventory at the end of 2023, as previously disclosed. Management had anticipated that this impact would be mitigated through a modest mid-year price increase along with new business acquired through expansion of its specialty pharmacy program. However, the full implementation and impact of this program expansion will not be fully realized until 2025. Based on the positive progress being made in reducing operating costs, the Company is raising the low end of its 2024 full year Adjusted EBITDA guidance to $16.0-16.7 million compared to the previous range of $15.5-16.7 million. HLS continues to expect that Vascepa will make a positive brand contribution to Adjusted EBITDA starting in Q4 2024. Finally, the Company is providing a preliminary outlook for 2025. HLS expects that revenue growth from its promoted product portfolio will be in the high single-digit percentage range while consolidated Adjusted EBITDA growth will be in the mid-20's percentage range. The Company will update its 2025 financial outlook when it releases its 2024 year-end results in March next year. Added Mr. Millian: "We are making progress in executing our plan, continuing to grow our promoted product portfolio while significantly reducing operating expenses and paying down debt. We believe the changes we are making this year will position HLS for top-line growth and increased profitability in 2025, while also creating greater flexibility for future capital allocation towards share buybacks and portfolio expansion opportunities." Q3 2024 FINANCIAL REVIEW The Company's Management's Discussion and Analysis and Consolidated Financial Statements for the three and nine months ended September 30, 2024, are available at the Company's website and at its profile at SEDAR+. Revenue Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Product sales Canada 11,087 10,153 30,878 28,755 United States 2,803 3,289 8,907 9,680 13,890 13,442 39,785 38,435 Royalty revenue 195 2,595 1,292 8,776 14,085 16,037 41,077 47,211 Revenue for the three and nine months ended September 30, 2024, decreased 12% and 13%, respectively, due to lower royalty revenues and was offset, in part, by growth of the Company's marketed products. Excluding royalties, revenue for the Company's marketed products (Vascepa, and Clozaril) for the three and nine months ended September 30, 2024, increased 3% and 4%, respectively, from the prior year periods. Product sales – Canada 000's of CAD Three months ended September 30, Nine months ended September 30, 2024 2023 % change 2024 2023 % change Clozaril 9,013 8,946 0.7 % 26,009 26,029 (0.1) % Vascepa 6,077 4,665 30.3 % 15,955 12,661 26.0 % Other 27 16 54 16 15,117 13,627 10.9 % 42,018 38,706 8.6 % Canadian product sales of Vascepa and Clozaril in Q3 2024 increased 11% in local currency, compared to Q3 2023, driven primarily by the 30% growth of Vascepa. For the nine months ended September 30, 2024, Canadian product sales of Vascepa and Clozaril increased 9% in local currency, compared to the same period in 2023. Product Sales – United States In the U.S. market, Clozaril revenue for the three and nine months ended September 30, 2024, decreased 15% and 8%, respectively, compared to the same periods in 2023. Results have been impacted by wholesaler purchasing patterns including a high level of wholesaler inventory at the start of the year and a key customer wholesaler transition that took place during Q3. Royalty revenues Royalty revenues for the three and nine months ended September 30, 2024, were down 92% and 85%, respectively, compared to the prior year periods as the term for Emblem, the largest royalty in the portfolio, came to an end midway through Q4 2023. Following the sale of the Xenpozyme royalty interest in Q2 2024, HLS has one remaining royalty interest which generated $0.2 million in revenue in Q3 2024. Operating Expenses Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Cost of product sales 2,235 1,870 6,312 5,091 Selling and marketing 4,208 5,048 13,295 15,180 Medical, regulatory and patient support 1,439 1,675 4,124 4,188 General and administrative 2,077 2,316 6,255 7,040 9,959 10,909 29,986 31,499 Cost of product sales was up for the three and nine months ended September 30, 2024, due primarily to higher Vascepa sales volumes. Excluding cost of product sales, operational expenses for the three and nine months ended September 30, 2024, decreased 15% and 10%, respectively, compared to the prior year periods. This was due to the Company's focus on cost management while continuing to support the growth potential of its marketed products. Sales and marketing expenses were lower in Q3 2024 in large part due to the discontinuation of co-promotional activities with the Company's marketing partner at the end of August 2024. Adjusted EBITDA1 Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Net loss for the period (4,844) (6,901) (16,632) (22,130) Stock-based compensation 511 (19) 1,194 63 Amortization and depreciation 5,508 8,207 17,283 24,892 Finance and related costs, net 2,389 4,223 7,998 9,128 Other costs (income) 621 42 (2,740) 4,106 Income tax expense (recovery) (59) (424) 3,988 (347) Adjusted EBITDA 4,126 5,128 11,091 15,712 Adjusted EBITDA for the three and nine months ended September 30, 2024, decreased due to the decline in royalty revenue and was offset in part by growth in the Company's marketed products. Excluding royalty revenue, Adjusted EBITDA for the three and nine months ended September 30, 2024, would have been approximately $3.9 million and $9.8 million, respectively, compared to $2.5 million and $6.9 million in the prior year periods, representing increases of 55% and 41%. The Company recorded Other Costs in Q3 2024 of approximately $0.6 million related to exiting its co-promotional agreement. For Q3 2024, the direct brand contribution from Clozaril to Adjusted EBITDA was $6.8 million, while the direct brand contribution from Vascepa to Adjusted EBITDA was a loss of $0.6 million. For the 2024 year-to-date period, the direct brand contribution from Clozaril to Adjusted EBITDA was $20.4 million, while the direct brand contribution from Vascepa to Adjusted EBITDA was a loss of $3.8 million. Net Loss Net loss for the three months ended September 30, 2024, was ($4.8) million, or ($0.15) per share, compared to a net loss of ($6.9) million, or ($0.21) per share, in Q3 2023. Net loss for the nine months ended September 30, 2024, was ($16.6) million, or ($0.52) per share, compared to a net loss of ($22.1) million, or ($0.68) per share, in the same period last year. Net loss improved in the year-over-year periods due primarily to lower operating expenses and lower amortization and depreciation expenses, which were offset, in part, by lower royalty revenue. Cash from Operations and Financial Position Cash generated from operations for the three and nine months ended September 30, 2024, was $1.5 million and $4.8 million, respectively, compared to $5.4 million and $12.1 million in the prior year periods. Cash was $17.5 million at September 30, 2024 compared to $22.0 million at December 31, 2023. Total borrowings under the credit agreement at September 30, 2024, were $70 million compared to $88.5 million at December 31, 2023. During the quarter, HLS made principal payments on its term loan totaling $15 million, which will save the Company an estimated $1.5 million annually in interest expense. Q3 2024 CONFERENCE CALL HLS will hold a conference call today at 8:30 am Eastern Time to discuss its Q3 2024 financial results. The call will be hosted by Mr. Craig Millian, CEO, Mr. John Hanna, CFO and Mr. Brian Walsh, CCO. To view the slides that accompany management's discussion, please use the webcast link. CONFERENCE ID: 84749 DATE: Thursday, November 7, 2024 TIME: 8:30 a.m. ET WEBCAST LINK: https://app.webinar.net/pK7MRDbWv52 TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or 1-416-945-7677 RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/4eQL014 TAPED REPLAY: 1-888-660-6345 or 1-289-819-1450 REPLAY CODE: 84749# The taped replay will be available for 14 days and the archived webcast will be available for 365 days. A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes before the conference call to ensure enough time for any software download required to hear the webcast. ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com 1CAUTIONARY NOTE REGARDING NON-IFRS MEASURES This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of HLS's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of HLS's financial information reported under IFRS. HLS uses non-IFRS measures to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. HLS also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. HLS's management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess HLS's ability to meet its future debt service, capital expenditure and working capital requirements. In particular, management uses Adjusted EBITDA as a measure of HLS's performance. To reconcile net income (loss) for the period with Adjusted EBITDA, each of (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "finance and related costs, net", (iv) "other costs (income)", and (v) "income tax expense (recovery)" appearing in the Consolidated Statement of Net Income (Loss) are added to net income (loss) for the period to determine Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies. Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS as issued by the IASB. 2CONSISTENT PRESCRIBER A consistent prescriber is a physician that has prescribed Vascepa in at least 4 of the past 5 weeks. FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 13, 2024, and Management's Discussion and Analysis dated November 6, 2024, both of which have been filed on SEDAR and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Unaudited [in thousands of U.S. dollars] As at As at September 30, 2024 December 31, 2023 ASSETS Current Cash 17,540 21,952 Accounts receivable 10,487 10,608 Inventories 7,683 9,534 Income taxes recoverable 98 86 Other current assets 1,766 1,915 Total current assets 37,574 44,095 Property, plant and equipment 897 965 Intangible assets 132,043 162,344 Deferred tax asset 619 1,037 Other non-current assets 607 619 Total assets 171,740 209,060 LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 13,482 14,107 Provisions 5,649 5,424 Debt and other liabilities 4,811 6,876 Income taxes payable 149 281 Total current liabilities 24,091 26,688 Debt and other liabilities 64,543 84,233 Deferred tax liability 3,777 442 Total liabilities 92,411 111,363 Shareholders' equity Share capital 260,595 262,127 Contributed surplus 14,907 13,865 Accumulated other comprehensive loss (5,016) (2,838) Deficit (191,157) (175,457) Total shareholders' equity 79,329 97,697 Total liabilities and shareholders' equity 171,740 209,060 HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF LOSS Unaudited [in thousands of U.S. dollars, except per share amounts] Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Revenue 14,085 16,037 41,077 47,211 Expenses Cost of product sales 2,235 1,870 6,312 5,091 Selling and marketing 4,208 5,048 13,295 15,180 Medical, regulatory and patient support 1,439 1,675 4,124 4,188 General and administrative 2,077 2,316 6,255 7,040 Stock-based compensation 511 (19) 1,194 63 Amortization and depreciation 5,508 8,207 17,283 24,892 Finance and related costs, net 2,389 4,223 7,998 9,128 Other costs (income) 621 42 (2,740) 4,106 Loss before income taxes (4,903) (7,325) (12,644) (22,477) Income tax expense (recovery) (59) (424) 3,988 (347) Net loss for the period (4,844) (6,901) (16,632) (22,130) Net loss per share: Basic and diluted $(0.15) $(0.21) $(0.52) $(0.68) HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Unaudited [in thousands of U.S. dollars] Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Net loss for the period (4,844) (6,901) (16,632) (22,130) Item that may be reclassified subsequently to net loss Unrealized foreign currency translation adjustment 1,158 (2,154) (2,178) 236 Comprehensive loss for the period (3,686) (9,055) (18,810) (21,894) HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Unaudited [in thousands of U.S. dollars] Share capital Contributed surplus Accumulated other comprehensive loss Deficit Total Balance, December 31, 2023 262,127 13,865 (2,838) (175,457) 97,697 Shares repurchased (1,532) — — 932 (600) Share purchase obligation — 300 — — 300 Stock option expense — 742 — — 742 Net loss for the period — — — (16,632) (16,632) Unrealized foreign currency translation adjustment — — (2,178) — (2,178) Balance, September 30, 2024 260,595 14,907 (5,016) (191,157) 79,329 Balance, December 31, 2022 265,206 13,821 (5,260) (148,449) 125,318 Stock options exercised 178 (44) — — 134 Shares repurchased (1,798) — — 826 (972) Share purchase obligation — (295) — — (295) Stock option expense — 693 — — 693 Net loss for the period — — — (22,130) (22,130) Dividends declared — — — (1,182) (1,182) Unrealized foreign currency translation adjustment — — 236 — 236 Balance, September 30, 2023 263,586 14,175 (5,024) (170,935) 101,802 HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited [in thousands of U.S. dollars] Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 OPERATING ACTIVITIES Net loss for the period (4,844) (6,901) (16,632) (22,130) Adjustments to reconcile net loss to cash provided by operating activities Stock-based compensation 511 (19) 1,194 63 Amortization and depreciation 5,508 8,207 17,283 24,892 Gain on royalty sale — — (3,381) — Impairment charge — — — 2,352 Accreted interest 353 199 912 580 Fair value adjustment on financial assets and liabilities 18 2,030 523 3,151 Deferred income taxes (47) (541) 3,753 (803) Net change in non-cash working capital balances related to operations 2 2,392 1,146 3,950 Cash provided by operating activities 1,501 5,367 4,798 12,055 INVESTING ACTIVITIES Proceeds from royalty sale — — 13,250 — Payment of purchase consideration (1,500) — (1,500) — Additions to property, plant and equipment — — (2) (27) Additions to intangible assets — (40) — (148) Cash provided by (used in) investing activities (1,500) (40) 11,748 (175) FINANCING ACTIVITIES Stock options exercised — — — 134 Shares repurchased — (603) (600) (972) Dividends paid — — — (2,398) Repayment of borrowing under credit agreement (14,965) (2,173) (18,533) (5,683) Debt costs — (1,360) (1,191) (1,360) Lease payments (131) (155) (386) (474) Cash used in financing activities (15,096) (4,291) (20,710) (10,753) Net increase (decrease) in cash during the period (15,095) 1,036 (4,164) 1,127 Foreign exchange on cash 120 (160) (248) (42) Cash, beginning of period 32,515 20,932 21,952 20,723 Cash, end of period 17,540 21,808 17,540 21,808 SOURCE HLS Therapeutics Inc.

TORONTO, Aug. 8, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Q2 2024 revenue was $14.5 million, Adjusted EBITDA1 was $4.3 million and cash from operations was $2.5 million, compared to $16.4 million, $5.5 million and $2.7 million, respectively, in Q2 2023. Sold the Xenpozyme royalty asset in a transaction valued at up to $45.75 million. Excluding royalty portfolio revenue, Q2 2024 revenue increased 9% to $14.1 million and Adjusted EBITDA increased 86% to $3.8 million, compared to $13.0 million and $2.1 million, respectively, in Q2 2023. Completed a Product Listing Agreement with the province of Alberta, for the listing and public reimbursement of Vascepa, effective August 1, 2024. "In Q2 we generated solid growth from our marketed products - Clozaril and Vascepa - particularly in Canada where sales grew 11% in local currency over prior year," said Craig Millian, CEO at HLS. "We also made progress against our strategic initiatives to drive future revenue growth and profitability, in part through effective cost management; of note, we reduced operating expenses by 13% while still generating growth from our marketed products. In addition, we strengthened our balance sheet and long-term financial flexibility by completing the sale of the Xenpozyme royalty interest, a non-strategic asset." Q2 2024 OTHER HIGHLIGHTS Clozaril revenue in Canada increased by 5% in local currency compared to Q2 2023. A study demonstrating the positive impact of pharmaceutical support programs on persistence with clozapine treatment was published in the Journal of Clinical Pharmacology and Therapeutics. Vascepa revenue in Canada increased 21% in local currency compared to Q2 2023. Vascepa unit demand increased by 45% compared to Q2 2023. The number of consistent prescribers2 for Vascepa increased 76% compared to Q2 2023. Finalized termination agreement with Pfizer to transition Vascepa primary care sales responsibilities back to HLS by August 31, 2024. BOARD OF DIRECTORS UPDATE Effective August 7, 2024, Laura Brege has decided to step down from the Board to focus on other endeavors. The Company is evaluating its board composition and will determine whether to fill the vacant position in due course. Norma Beauchamp, one of the Company's current Compensation and Governance Committee members, will replace Ms. Brege as Chair of that Committee. "On behalf of the Board and HLS Management, I want to thank Laura for the insights, guidance and leadership she provided during her five years on the Board. We wish her the best in all her future pursuits," said John Welborn, Chair of the Board at HLS. 2024 OUTLOOK With the release of its Q2 2024 results, the Company reiterates its 2024 guidance, which was updated following the sale of the Xenpozyme royalty interest. 2024 consolidated revenue guidance is $58.5 to $59.7 million. Comprising that number is Vascepa revenue of $17 to $18 million (C$22.5 to $24.5 million), Clozaril revenue of approximately $40 million and royalty portfolio revenue of $1.5 to $1.7 million. 2024 Adjusted EBITDA is expected to be $15.5 to $16.7 million. As communicated previously HLS expects Vascepa to make a positive contribution to Adjusted EBITDA starting in the fourth quarter, which would position the Company to enter 2025 with a growth portfolio of two profitable products, Clozaril and Vascepa. Mr. Millian added: "We look to build-on the positive momentum generated in Q2 to drive a strong second half of the year for our marketed products. With Clozaril, our regional strategies are having a positive impact, and, in Canada, we are seeing encouraging growth trends. Additionally, we expect Vascepa to benefit over the remainder of the year driven by the evolution of our go-to-market model as well as the recent public plan listings in BC and Alberta." Q2 2024 FINANCIAL REVIEW The Company's Management's Discussion and Analysis and Consolidated Financial Statements for the three and six months ended June 30, 2024, are available at the Company's website and at its profile at SEDAR+. Revenue Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Product sales Canada 10,637 9,791 19,791 18,602 United States 3,462 3,179 6,104 6,391 14,099 12,970 25,895 24,993 Royalty revenue 420 3,447 1,097 6,181 14,519 16,417 26,992 31,174 Revenue for the three and six months ended June 30, 2024, decreased 12% and 13%, respectively, due to lower royalty revenues and offset, in part, by growth of the Company's marketed products. Excluding royalties, revenue for the Company's marketed products (Vascepa, and Clozaril) for the three and six months ended June 30, 2024, increased 9% and 4%, respectively, from the prior year periods. Product sales – Canada 000's of CAD Three months ended June 30, Six months ended June 30, 2024 2023 % change 2024 2023 % change Clozaril 9,131 8,665 5.4 % 16,996 17,083 (0.5) % Vascepa 5,407 4,481 20.7 % 9,878 7,996 23.5 % Other 14 — 27 — 14,552 13,146 10.7 % 26,901 25,079 7.3 % Canadian product sales of Vascepa and Clozaril in Q2 2024 increased 11% in local currency, compared to Q2 2023. Q2 2024 revenue in Canada from Vascepa and Clozaril increased 21% and 5% year-over-year, respectively, in local currency. For the six months ended June 30, 2024, Canadian product sales of Vascepa and Clozaril increased 7% in local currency, compared to the same period in 2023. For the six months ended June 30, 2024, in local currency, revenue in Canada from Vascepa and Clozaril increased 23.5% and decreased 0.5%, respectively, compared to the same period last year. Product Sales – United States In the U.S., Clozaril revenue in Q2 2024 increased 9% compared to Q2 2023. For the six months ended June 30, 2024, Clozaril revenue in the U.S. decreased 5% compared to the same period in 2023. Key demand fundamentals remain in place with the year-to-date revenue variance to the prior year period largely due to wholesalers in the U.S. ending 2023 with an unusually high level of inventory, which impacted sales in Q1 2024. Royalty revenues Royalty revenues for the three and six months ended June 30, 2024, were down 88% and 82%, respectively, compared to the prior year periods as the term for what was the largest royalty in the portfolio came to an end midway through Q4 2023. Following the sale of the Xenpozyme royalty interest in Q2 2024, HLS has one remaining royalty interest, which is for Obizur. Obizur is a treatment to help control bleeding in acquired "Hemophilia A" and is marketed by Takeda Pharmaceuticals. Operating Expenses Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Cost of product sales 2,303 1,777 4,077 3,221 Selling and marketing 4,561 5,325 9,087 10,132 Medical, regulatory and patient support 1,420 1,437 2,685 2,513 General and administrative 1,977 2,373 4,178 4,724 10,261 10,912 20,027 20,590 Excluding cost of product sales, operational expenses for the three and six months ended June 30, 2024, decreased 13% and 8%, respectively, compared to the prior year periods. This was due to the Company's focus on cost management while continuing to support the growth potential of its marketed products. "With the primary care sales function transition to HLS expected to be completed by the end of August, we anticipate a further reduction in operational expenses for Q4 this year and beyond," said John Hanna, CFO at HLS. "Overall, this transition is projected to save the Company around $5 million annually. Most of these savings will fall directly to our bottom line, after accounting for some modest reinvestment in expanding the Vascepa salesforce and supporting other reimbursement and retention initiatives." Cost of product sales was up for the for the three and six months ended June 30, 2024, due to higher Vascepa sales volumes. Adjusted EBITDA1 Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Net loss for the period (5,682) (9,437) (11,788) (15,229) Stock-based compensation 427 137 683 82 Amortization and depreciation 5,856 8,366 11,775 16,685 Finance and related costs, net 2,942 2,471 5,609 4,905 Other costs (income) (3,361) 3,851 (3,361) 4,064 Income tax expense 4,076 117 4,047 77 Adjusted EBITDA 4,258 5,505 6,965 10,584 Adjusted EBITDA for the three and six months ended June 30, 2024, decreased $1.2 million and $3.6 million, respectively, compared to the prior year periods. The decrease was due to the decline in royalty revenue and was offset in part by growth in the Company's marketed products. Excluding royalty revenue, Adjusted EBITDA for the three and six months ended June 30, 2024, would have been approximately $3.8 million and $5.9 million, respectively, compared to $2.1 million and $4.4 million in the prior year periods, representing increases of 86% and 33%. For Q2 2024, the direct brand contribution from Clozaril to Adjusted EBITDA was $7.6 million, while the direct brand contribution from Vascepa to Adjusted EBITDA was a loss of $1.6 million. For the 2024 year-to-date period, the direct brand contribution from Clozaril to Adjusted EBITDA was $13.7 million, while the direct brand contribution from Vascepa to Adjusted EBITDA was a loss of $3.2 million. Net Loss Net loss for the three months ended June 30, 2024, was ($5.7) million, or ($0.18) per share, compared to a net loss of ($9.4) million, or ($0.29) per share, in Q2 2023. Net loss for the six months ended June 30, 2024, was ($11.8) million, or ($0.37) per share, compared to a net loss of ($15.2) million, or ($0.47) per share, in the same period last year. Net loss improved in the year-over-year periods due primarily to lower operating expenses and lower amortization and depreciation expense as well as recording other income versus other costs in the prior year periods, which were offset, in part, by lower royalty revenue. Cash from Operations and Financial Position Cash generated from operations for the three and six months ended June 30, 2024, was $2.5 million and $3.3 million, respectively, compared to $2.7 million and $6.7 million in the prior year periods. Cash was $32.5 million at June 30, 2024 compared to $22.0 million at December 31, 2023. Cash at June 30, 2024, included $13.25 million received in the sale of the Xenpozyme royalty interest. Total borrowings under the credit agreement at June 30, 2024, was $84.9 million compared to $88.5 million at December 31, 2023. Subsequent to quarter end, HLS made a $14 million principal payment on its term loan, reducing the term loan outstanding at the time of payment to approximately $71 million. This principal payment will save the Company approximately $1.5 million annually in interest expense. Q2 2024 CONFERENCE CALL HLS will hold a conference call today at 8:30 am Eastern Time to discuss its Q2 2024 financial results. The call will be hosted by Mr. Craig Millian, CEO, and Mr. John Hanna, Interim CFO. To view the slides that accompany management's discussion, please use the webcast link. CONFERENCE ID: 58793 DATE: Thursday, August 8, 2024 TIME: 8:30 a.m. ET WEBCAST LINK: https://app.webinar.net/Bo1rqAKyNm9 TRADITIONAL DIAL-IN NUMBER: 1-800-836-8184 or 1-289-819-1350 RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3xE2Dl5 TAPED REPLAY: 1-888-660-6345 or 1-289-819-1450 REPLAY CODE: 58793# The taped replay will be available for 14 days and the archived webcast will be available for 365 days. A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes before the conference call to ensure enough time for any software download required to hear the webcast. ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com 1CAUTIONARY NOTE REGARDING NON-IFRS MEASURES This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of HLS's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of HLS's financial information reported under IFRS. HLS uses non-IFRS measures to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. HLS also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. HLS's management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess HLS's ability to meet its future debt service, capital expenditure and working capital requirements. In particular, management uses Adjusted EBITDA as a measure of HLS's performance. To reconcile net income (loss) for the period with Adjusted EBITDA, each of (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "finance and related costs, net", (iv) "other costs (income)", and (v) "income tax expense" appearing in the Consolidated Statement of Net Income (Loss) are added to net income (loss) for the period to determine Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies. Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS as issued by the IASB. 2CONSISTENT PRESCRIBER A consistent prescriber is a physician that has prescribed Vascepa in at least 4 of the past 5 weeks. FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 13, 2024, and Management's Discussion and Analysis dated August 7, 2024, both of which have been filed on SEDAR and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Unaudited [in thousands of U.S. dollars] As at As at June 30, 2024 December 31, 2023 ASSETS Current Cash 32,515 21,952 Accounts receivable 9,115 10,608 Inventories 8,796 9,534 Income taxes recoverable 95 86 Other current assets 2,338 1,915 Total current assets 52,859 44,095 Property, plant and equipment 701 965 Intangible assets 136,387 162,344 Deferred tax asset 777 1,037 Other non-current assets 598 619 Total assets 191,322 209,060 LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 12,317 14,107 Provisions 7,054 5,424 Debt and other liabilities 6,591 6,876 Income taxes payable 158 281 Total current liabilities 26,120 26,688 Debt and other liabilities 78,514 84,233 Deferred tax liability 3,982 442 Total liabilities 108,616 111,363 Shareholders' equity Share capital 260,595 262,127 Contributed surplus 14,598 13,865 Accumulated other comprehensive loss (6,174) (2,838) Deficit (186,313) (175,457) Total shareholders' equity 82,706 97,697 Total liabilities and shareholders' equity 191,322 209,060 HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF LOSS Unaudited [in thousands of U.S. dollars, except per share amounts] Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Revenue 14,519 16,417 26,992 31,174 Expenses Cost of product sales 2,303 1,777 4,077 3,221 Selling and marketing 4,561 5,325 9,087 10,132 Medical, regulatory and patient support 1,420 1,437 2,685 2,513 General and administrative 1,977 2,373 4,178 4,724 Stock-based compensation 427 137 683 82 Amortization and depreciation 5,856 8,366 11,775 16,685 Finance and related costs, net 2,942 2,471 5,609 4,905 Other costs (income) (3,361) 3,851 (3,361) 4,064 Loss before income taxes (1,606) (9,320) (7,741) (15,152) Income tax expense 4,076 117 4,047 77 Net loss for the period (5,682) (9,437) (11,788) (15,229) Net loss per share: Basic and diluted $(0.18) $(0.29) $(0.37) $(0.47) HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Unaudited [in thousands of U.S. dollars] Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Net loss for the period (5,682) (9,437) (11,788) (15,229) Item that may be reclassified subsequently to net loss Unrealized foreign currency translation adjustment (963) 2,297 (3,336) 2,390 Comprehensive loss for the period (6,645) (7,140) (15,124) (12,839) HLS THERAPEUTICS INC. INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Unaudited [in thousands of U.S. dollars] Share capital Contributed surplus Accumulated other comprehensive loss Deficit Total Balance, December 31, 2023 262,127 13,865 (2,838) (175,457) 97,697 Shares repurchased (1,532) — — 932 (600) Share purchase obligation — 300 — — 300 Stock option expense — 433 — — 433 Net loss for the period — — — (11,788) (11,788) Unrealized foreign currency translation adjustment — — (3,336) — (3,336) Balance, June 30, 2024 260,595 14,598 (6,174) (186,313) 82,706 Balance, December 31, 2022 265,206 13,821 (5,260) (148,449) 125,318 Stock options exercised 178 (44) — — 134 Shares repurchased (623) — — 254 (369) Share purchase obligation — (305) — — (305) Stock option expense — 679 — — 679 Net loss for the period — — — (15,229) (15,229) Dividends declared — — — (1,182) (1,182) Unrealized foreign currency translation adjustment — — 2,390 — 2,390 Balance, June 30, 2023 264,761 14,151 (2,870) (164,606) 111,436 HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited [in thousands of U.S. dollars] Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 OPERATING ACTIVITIES Net loss for the period (5,682) (9,437) (11,788) (15,229) Adjustments to reconcile net loss to cash provided by operating activities Stock-based compensation 427 137 683 82 Amortization and depreciation 5,856 8,366 11,775 16,685 Gain on royalty sale (3,381) — (3,381) — Impairment charge — 2,352 — 2,352 Accreted interest 277 190 559 381 Fair value adjustment on financial assets and liabilities 318 570 505 1,121 Deferred income taxes 3,861 (85) 3,800 (262) Net change in non-cash working capital balances related to operations 843 575 1,144 1,558 Cash provided by operating activities 2,519 2,668 3,297 6,688 INVESTING ACTIVITIES Proceeds from royalty sale 13,250 — 13,250 — Additions to property, plant and equipment — (27) (2) (27) Additions to intangible assets — (108) — (108) Cash provided by (used in) investing activities 13,250 (135) 13,248 (135) FINANCING ACTIVITIES Stock options exercised — — — 134 Shares repurchased (317) (185) (600) (369) Dividends paid — (1,216) — (2,398) Repayment of borrowing under credit agreement (1,493) (1,389) (3,568) (3,510) Debt costs (658) — (1,191) — Lease payments (112) (158) (255) (319) Cash used in financing activities (2,580) (2,948) (5,614) (6,462) Net increase (decrease) in cash during the period 13,189 (415) 10,931 91 Foreign exchange on cash (117) 133 (368) 118 Cash, beginning of period 19,443 21,214 21,952 20,723 Cash, end of period 32,515 20,932 32,515 20,932 SOURCE HLS Therapeutics Inc.